A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment.
We have reviewed results of therapy in 740 patients with grades II-IV acute graft-versus-host disease (GVHD) after allogeneic marrow transplantation. At the beginning of therapy, 597 patients (81%) had rash, 369 (50%) had liver dysfunction and 396 (54%) had gut dysfunction. Initial treatment was with glucocorticoids (n = 531), cyclosporine (n = 170), antithymocyte globulin (ATG) (n = 156) or monoclonal antibody (n = 3) either singly (n = 633) or in combination (n = 107). Parameters of GVHD severity in each organ were recorded weekly, and evaluation of response was made using values at the initiation of secondary treatment or, for patients without such treatment, using values on day 29 of primary treatment or the last recorded value before death, whichever occurred first. Minimal criteria for improvement or progression were defined for each organ, but no attempt was made to define liver or gut outcome if another complication such as venocclusive disease or infectious enteritis was present. Improvement rates were 43% for skin disease, 35% for evaluable liver disease and 50% for evaluable gut disease. Overall complete or partial responses were seen in 44% of patients. Multivariate analyses were carried out to identify patient, disease or treatment factors associated with likelihood of overall improvement and likelihood of response in at least one organ. A similar analysis was also carried out to identify covariates associated with time to treatment failure (defined as initiation of secondary therapy or death not due to relapse of malignancy). In all three models, GVHD prophylaxis using cyclosporine combined with methotrexate was associated with favorable GVHD treatment outcome compared to prophylaxis with either agent alone, and treatment with glucocorticoids or cyclosporine was more successful than treatment with ATG. Other factors associated with unfavorable outcome in the model of time to treatment failure and also entered in one of the response models were recipient HLA disparity with the donor, presence of a liver complication other than GVHD, and early onset of GVHD. Results of this analysis indicate that glucocorticoids represent the best initial therapy available for treatment of acute GVHD, although much room for improvement remains.
Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98104.
P J
PJ
Martin
G
G
Schoch
L
L
Fisher
V
V
Byers
C
C
Anasetti
F R
FR
Appelbaum
P G
PG
Beatty
K
K
Doney
G B
GB
McDonald
J E
JE
Sanders
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D003524:Cyclosporins / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use; D006086:Graft vs Host Disease / Q000517:prevention & control / Q000628:therapy*; D006801:Humans; D007410:Intestinal Diseases / Q000209:etiology / Q000628:therapy; D008107:Liver Diseases / Q000209:etiology / Q000628:therapy; D008727:Methotrexate / Q000627:therapeutic use; D015999:Multivariate Analysis; D012189:Retrospective Studies; D012871:Skin Diseases / Q000209:etiology / Q000628:therapy
D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D003524:Cyclosporins; D005938:Glucocorticoids; D008727:Methotrexate